We are live on
!
Find out more
Denali Therapeutics
DNLI
DNLI
114 hedge funds and large institutions have $1.49B invested in Denali Therapeutics in 2019 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 42 increasing their positions, 24 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
223% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $328K
75% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 24
2.47% more ownership
Funds ownership: 72.48% → 74.94% (+2.5%)
10% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 21
0% more funds holding
Funds holding: 114 → 114 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less capital invested
Capital invested by funds: $1.6B → $1.49B (-$118M)
Holders
114
Holders Change
–
Holders Change %
0%
% of All Funds
2.48%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
23
Increased
42
Reduced
24
Closed
21
Calls
$1.06M
Puts
$328K
Net Calls
+$731K
Net Calls Change
+$685K
Top Buyers
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$25.7M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$16.6M |
| 3 |
BlackRock
New York
|
+$13.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$6.98M |
| 5 |
CC
Casdin Capital
New York
|
+$6.72M |
Top Sellers
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$20M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.94M |
| 4 |
LCG
Lisanti Capital Growth
New York
|
-$1.71M |
| 5 |
Squarepoint
New York
|
-$1.66M |
